SCHEMBL1815768

SCHEMBL1815768

COC(=O)c1cccc(NC(=O)c2cccnc2Cl)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.62
KMT2A Q03164 3/20 0.62
RAB9A P51151 8/20 0.61
ALDH1A1 P00352 3/20 0.59
NPC1 O15118 5/20 0.57
POLB P06746 1/20 0.57
PKM P14618 1/20 0.57
MAPT P10636 4/20 0.55
SMN1; SMN2 Q16637 4/20 0.55
TP53 P04637 1/20 0.54
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
MAPK1 P28482 1/20 0.53
HTT P42858 2/20 0.52
GFER P55789 1/20 0.52
HPGD P15428 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13235120 0.91 RAB9A (0.71) MEN1KMT2ARAB9AALDH1A1NPC1
SCHEMBL2490668 0.88 RAB9A (0.67) MEN1KMT2ARAB9AALDH1A1NPC1
SCHEMBL1814793 0.86 MEN1 (0.67) MEN1KMT2ARAB9AALDH1A1NPC1
SCHEMBL1805499 0.86 MEN1 (0.67) MEN1KMT2ARAB9AALDH1A1NPC1
SCHEMBL1810078 0.85 RAB9A (0.59) MEN1KMT2ARAB9AALDH1A1NPC1
SCHEMBL28004406 0.85 KMT2A (0.69) MEN1KMT2ARAB9AALDH1A1NPC1
Hydrochloric Acid SCHEMBL2106811 0.85 MEN1 (0.65) MEN1KMT2ARAB9AALDH1A1NPC1
SCHEMBL1499540 0.84 GRM4 (0.68) MEN1KMT2ARAB9AALDH1A1NPC1
SCHEMBL23367919 0.82 ALDH1A1 (0.64) MEN1KMT2AALDH1A1NPC1MAPT
SCHEMBL1813249 0.82 RAB9A (0.81) MEN1KMT2ARAB9AALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110201603-A1 Novel Acylaminobenzamide Derivatives BAYER CROPSCIENCE AG (DE) 2011-08-18 US disclosed
EP-2318358-A2 ACYLAMINOBENZAMIDE DERIVATIVES Bayer CropScience AG (DE) 2011-05-11 EP disclosed
WO-2010015355-A2 NOVEL ACYLAMINOBENZAMIDE DERIVATIVES BAYER CROPSCIENCE AG (DE) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201603-A1 Novel Acylaminobenzamide Derivatives KCNB1, KCNA5, KCNA7 MEN1 3469/4885KMT2A 676/4885RAB9A 742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.